Drug Trial Radar · NCT06915142
A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Apr 28, 2025
Primary completion
Dec 2026
Study completion Oct 2027
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicentre, open phase II clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. To evaluate the safety, tolerability and efficacy of HRS-7058 in combination with antitumor drugs.
Conditions
- Advanced Malignant Tumour
Interventions
HRS-7058 + SHR-1316Drug
HRS-7058 + SHR-1316
HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapyDrug
HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy
HRS-7058 + CetuximabDrug
HRS-7058 + Cetuximab
HRS-7058 + SHR-1826Drug
HRS-7058 + SHR-1826
HRS-7058 + SHR-1826 + SHR-1316Drug
HRS-7058 + SHR-1826 + SHR-1316
HRS-7058 + SHR-A1202Drug
HRS-7058 + SHR-A1202
HRS-7058 + BP102Drug
HRS-7058 + BP102
HRS-7058 + SHR-9839Drug
HRS-7058 + SHR-9839
HRS-7058 +SHR-A2102 +SHR-1316Drug
HRS-7058 +SHR-A2102 +SHR-1316
HRS-7058 +SHR-9839(sc)+SHR-1316Drug
HRS-7058 +SHR-9839(sc)+SHR-1316
HRS-7058 +SHR-1316 +BP102Drug
HRS-7058 +SHR-1316 +BP102
HRS-7058 +SHR-A2102 +BP102Drug
HRS-7058 +SHR-A2102 +BP102
HRS-7058 +SHR-A2102 +SHR-1316 +BP102Drug
HRS-7058 +SHR-A2102 +SHR-1316 +BP102
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT) (Dose Escalation and Dose Expansion)Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months
- Safety endpoints: adverse events (AE) (Dose Escalation and Dose Expansion)Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months]
- Phase II recommended dose (RP2D)(Dose Escalation and Dose Expansion)Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months]
- Efficacy endpoints: Objective response rate (ORR) assessed based on RECIST v1.1 criterion (Efficacy Expansion)Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China · Recruiting
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.